Pipeline

March 18, 2019

Company	Drug/Device	Medical Condition	Status
Rocket Pharmaceuticals, Inc.	RP-L102	Fanconi Anemia (FA)	Phase I trial initiated enrolling 2 FA pediatric subjects
Infinity Pharmaceuticals, Inc.	IPI-549	triple negative breast cancer (TNBC) and renal cell cancer (RCC)	Phase II trial initiated
Theravance Biopharma, Inc.	TD-1473	moderately to severely active ulcerative colitis	Phase IIb/III trial initiated
Biohaven Pharmaceutical Holding Company Ltd.	troriluzole	Spinocerebellar Ataxia (SCA)	Phase III trial initiated enrolling 230 subjects at approximately 22 sites in the U.S.
Alvotech	AVT02	moderate to severe chronic plaque psoriasis	Phase III trial initiated enrolling 400 subjects at approximately 30 sites in Europe
Helsinn Group	anamorelin	advanced NSCLC with cachexia	Phase III trial initiated
Santhera Pharmaceuticals AG	Raxone	Leber’s hereditary optic neuropathy (LHON)	Phase IV trial initiated enrolling 197 subjects in 31 sites across nine European countries and the U.S.
Nvision Biomedical Technologies	Vector Hammertoe Correction System	foot and ankle procedures	510(k) clearance granted by the FDA
Sonavex, Inc.	EchoSure	blood flow monitoring	510(k) clearance granted by the FDA
Instrumentation Laboratory	GEM Premier ChemSTAT in vitro diagnostic (IVD) analyzer with Intelligent Quality Management (iQM)	rapid basic metabolic panel (BMP) testing at the point of care for diagnosing acute conditions, such as kidney failure, insulin shock, respiratory distress and arrhythmias	510(k) clearance granted by the FDA
Purdue Pharma L.P.	nalmefene hydrochloride (HCl) injection	emergency treatment of known or suspected opioid overdose	Fast Track designation granted by the FDA
Alkem Laboratories Limited	Valsartan (generic Diovan)	high blood pressure and heart failure	Approval granted by the FDA
Aerie Pharmaceuticals, Inc.	Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%	open-angle glaucoma or ocular hypertension	Approval granted by the FDA
Genentech	Tecentriq (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albuminbound); nab-paclitaxel])	unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumors express PD-L1, as determined by an FDA-approved test	Approval granted by the FDA
Pfizer, Inc.	TRAZIMERA (trastuzumab-qyyp)	human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma	Approval granted by the FDA